Christoph Stange

Christoph Stange is a Postdoctoral researcher in precision oncology at Technische Universität München since September 2023, focusing on evaluating new tailored therapy options for refractory cancer patients using proteomics. Previously, Christoph served as a doctoral researcher at Klinikum rechts der Isar der TU München from September 2017 to September 2023, working on improving ovarian cancer therapies with an emphasis on the interplay between drug toxicity and the immune system for personalized patient care. Prior to this, Christoph gained practical experience as an intern at Beckord & Niedlich Patentanwälte, where responsibilities included authoring patent applications. Christoph holds a Master of Science in molecular biotechnology and a Bachelor of Science in molecular biotechnology, both from Technical University of Munich, completed between 2010 and 2016.